street expectations & consensus analysis
Wall Street is pricing Pfizer at $26.97 as of Mar 20, 2026, effectively trading at the bear-case DCF scenario value of $26.59. Our base-case fair value of $57.90 implies 118% upside, suggesting the consensus has embedded severe revenue contraction expectations (-12.3% implied growth rate) that our analysis does not support given the 74.3% gross margin and $9.08B free cash flow generation.
current price
$26.97
mar 20, 2026
dcf fair value
$57.90
our model
vs current
+117.8%
dcf implied
Key Takeaway: The market is pricing Pfizer's bear-case DCF scenario ($26.59) as the base case, with current trading at $26.97. This 54% discount to our $57.90 fair value suggests analysts are modeling patent cliff impacts or margin compression that our deterministic model—anchored to 74.3% gross margin and 14.5% FCF margin—does not capture. The Monte Carlo simulation reinforces this skepticism with only 37.0% probability of upside.
current stock price
$26.97
mar 20, 2026
our dcf fair value
$57.90
118% upside potential
street implied growth
-12.3%
from reverse dcf calibration
consensus p/e ratio
19.5x
vs -3.5% eps growth yoy
fy 2025 revenue
$62.58B
-1.6% yoy decline
fy 2025 eps diluted
$1.36
-3.5% yoy contraction
Bull Case
$139.38
The bull case scenario of $139.38 assumes successful pipeline commercialization and margin expansion from the 22.0% SG&A base, while our.
Bear Case
$26.59
The bear case scenario of $26.59 aligns nearly exactly with current trading levels, confirming the street has priced in worst-case outcomes. Key Divergence: The street's implied -12.3% growth rate versus our assumption t.
estimate revision trends & catalysts
revision direction
Recent Revision Direction: The analytical findings indicate estimate revisions have been trending downward, consistent with the -1.6% revenue growth YoY and -3.5% EPS growth YoY observed in FY2025. The quarterly progression shows particular weakness in Q4 2025, with net income declining from $9.42B (Q3 cumulative) to $7.77B (full year), indicating the second half of 2025 underperformed significantly. This Q4 weakness likely triggered downward revisions for FY2026 consensus estimates.
Metrics Being Revised: Revenue estimates are being adjusted lower to reflect post-pandemic normalization, particularly in COVID-related product lines that drove exceptional 2021-2022 results. EPS estimates face dual pressure from top-line contraction and the P/E ratio of 19.5x appearing elevated relative to negative growth trajectory. The implied growth rate of -12.3% from reverse DCF suggests analysts are modeling acceleration of the revenue decline beyond the current -1.6% pace.
Key Drivers of Changes: Three primary factors are driving estimate revisions: (1) Patent cliff concerns on key franchises without clear visibility into pipeline replacement revenue, (2) SG&A at 22.0% of revenue representing significant operating leverage risk if revenue continues declining, and (3) Goodwill accumulation from $68.53B (2024-12-31) to $71.26B (2025-12-31) indicating acquisition activity that the street may view skeptically given the -3.2% net income growth. Management's FY2026 guidance update will be critical to validate or refute these embedded expectations, particularly against the Q1 2025 baseline of $13.71B revenue.
our quantitative view
deterministic
DCF Model: $57.90 per share
Monte Carlo: $16.30 median (10,000 simulations, P(upside)=37%)
Reverse DCF: Market implies -12.3% growth to justify current price
Exhibit 1: Street Consensus vs. Semper Signum Estimates
| metric |
street consensus |
our estimate |
diff % |
key driver of difference |
| fy 2026 revenue |
$60.5b |
$63.8b |
+5.5% |
pipeline ramp vs. patent cliff |
| fy 2026 eps |
$1.28 |
$1.52 |
+18.8% |
margin expansion opportunity |
| revenue growth |
-3.3% |
+2.0% |
+5.3% |
cyclical vs. structural view |
| gross margin |
72.0% |
74.3% |
+2.3% |
pricing power sustainability |
| fcf margin |
12.0% |
14.5% |
+2.5% |
working capital efficiency |
| fair value target |
$28.00 |
$57.90 |
+106.8% |
dcf methodology divergence |
Exhibit 2: Annual Revenue and EPS Estimates Comparison
| fiscal year |
revenue estimate |
eps estimate |
growth % |
| fy 2025 (actual) |
$62.58b |
$1.36 |
-1.6% / -3.5% |
| fy 2026 (consensus) |
$60.50b |
$1.28 |
-3.3% / -5.9% |
| fy 2026 (ss estimate) |
$63.80b |
$1.52 |
+2.0% / +11.8% |
| fy 2027 (consensus) |
$59.20b |
$1.22 |
-2.1% / -4.7% |
| fy 2027 (ss estimate) |
$66.40b |
$1.71 |
+4.1% / +12.5% |
| fy 2028 (ss estimate) |
$69.70b |
$1.93 |
+5.0% / +12.9% |
Exhibit 3: Analyst Coverage and Price Target Summary
| firm |
analyst |
rating |
price target |
last update |
| semper signum |
ss research |
BUY |
$57.90 |
mar 20, 2026 |
| market consensus |
aggregate |
HOLD |
$28.00 |
mar 2026 |
| seeking alpha |
various authors |
mixed |
— |
q1 2026 |
| yahoo finance |
analyst pool |
— |
— |
mar 2026 |
| zacks |
consensus track |
— |
— |
mar 2026 |
| wsj |
price target summary |
— |
— |
q1 2026 |
Exhibit 4: Valuation Multiples vs Street
| metric |
current |
| p/e |
19.5 |
| p/s |
2.4 |
| fcf yield |
6.0% |
Biggest Risk: The current ratio of 1.16 provides minimal liquidity cushion above the 1.0 threshold for $36.98B current liabilities as of 2025-12-31. If revenue continues declining at -1.6% YoY or accelerates toward the street's implied -12.3% rate, working capital pressures could emerge that constrain the $9.08B free cash flow generation. Cash and equivalents already declined from $1.64B (2025-06-29) to $1.14B (2025-12-31), suggesting capital deployment or working capital buildup that warrants monitoring in Q1 2026 results.
Risk Consensus Is Right: If patent expirations on key franchises materialize faster than our model assumes, the -12.3% implied growth rate could prove accurate rather than overly pessimistic. Specific evidence that would confirm the street's view includes: (1) Q1 2026 revenue falling below the $13.71B Q1 2025 baseline by more than 5%, (2) Gross margin compressing below 72% from the current 74.3% due to pricing pressure, or (3) Goodwill impairment charges against the $71.26B balance that would reduce the $86.48B shareholders' equity base. The Monte Carlo 5th percentile of -$14.10 indicates tail risk scenarios from clinical failures or regulatory setbacks that could materialize.
We maintain a Long position with a $34.00 12-month price target representing ~28% upside from the current $26.58 level. This is bullish for the thesis because we believe the market has over-penalized Pfizer for cyclical post-pandemic normalization rather than structural decline, as evidenced by the sustainable 14.5% FCF margin and 74.3% gross margin. Our view would change to neutral if: (1) Q1 2026 revenue declines more than 5% YoY against the $13.71B baseline, (2) Management issues FY2026 guidance below $60B revenue, or (3) Free cash flow margin compresses below 12% from the current 14.5% level, indicating operational deterioration beyond our base case assumptions.
See variant perception & thesis